Heartflow (NASDAQ:HTFL) Insider Sells $987,052.30 in Stock

Heartflow, Inc. (NASDAQ:HTFL) insider Campbell Rogers sold 19,682 shares of the company’s stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $50.15, for a total value of $987,052.30. Following the completion of the sale, the insider owned 79,956 shares of the company’s stock, valued at approximately $4,009,793.40. The trade was a 19.75% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Campbell Rogers also recently made the following trade(s):

• On Monday, August 17th, Campbell Rogers sold 9,219 shares of Heartflow stock. The shares were sold at an average price of $41.23, for a total value of $380,099.37.

Heartflow Price Performance

Shares of NASDAQ:HTFL traded down $0.42 during mid-day trading on Monday, reaching $50.33. 1,379,826 shares of the company traded hands, compared to its average volume of 1,591,831. The company’s 50 day moving average price is $37.75 and its 200-day moving average price is $31.75. The firm has a market cap of $4.38 billion and a PE ratio of -27.50. Heartflow, Inc. has a 52 week low of $20.13 and a 52 week high of $52.22.

Heartflow (NASDAQ:HTFL) last released its earnings results on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.15. The company had revenue of $64.08 million for the quarter. Heartflow had a negative net margin of 55.82% and a negative return on equity of 23.52%. The business’s revenue for the quarter was up 47.7% on a year-over-year basis. On average, research analysts predict that Heartflow, Inc. will post -0.75 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on HTFL shares. Wells Fargo & Company upped their target price on shares of Heartflow from $37.00 to $39.00 and gave the stock an “overweight” rating in a report on Friday, August 14th. UBS Group started coverage on Heartflow in a report on Wednesday, September 9th. They set a “neutral” rating and a $55.00 price target on the stock. Weiss Ratings raised Heartflow from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 7th. Benchmark reiterated a “buy” rating on shares of Heartflow in a research report on Friday, August 14th. Finally, Freedom Capital raised Heartflow to a “strong-buy” rating in a research note on Tuesday, June 30th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Heartflow presently has a consensus rating of “Moderate Buy” and an average price target of $44.88.

Institutional Trading of Heartflow

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. XXEC Inc. bought a new position in shares of Heartflow during the 2nd quarter valued at about $2,524,764,000. BlackRock Inc. bought a new stake in shares of Heartflow in the second quarter worth about $152,502,000. Bamco Inc. NY purchased a new stake in shares of Heartflow in the second quarter worth about $94,625,000. Jupiter Topco LLC bought a new stake in Heartflow in the 2nd quarter worth approximately $70,983,000. Finally, Janus Henderson Group PLC raised its holdings in shares of Heartflow by 152.0% during the 1st quarter. Janus Henderson Group PLC now owns 2,180,976 shares of the company’s stock worth $53,063,000 after acquiring an additional 1,315,416 shares in the last quarter.

About Heartflow

Heartflow, Inc is a medical technology company that develops artificial intelligence and imaging solutions for the diagnosis and management of coronary artery disease. Its platform analyzes data from coronary computed tomography angiography (CCTA) scans to create personalized, three-dimensional models of a patient’s coronary arteries.

The company’s primary offering, Heartflow Analysis, is designed to provide noninvasive estimates of fractional flow reserve derived from computed tomography (FFR^CT).